Search

Pump Therapy Candidate Assessment

GettyImages-1296068796_700x400
Pump therapy success requires proper assessment of the candidate.

Content Developed By: ADCES Tech Committee and the danatech staff

 

Assessing the Readiness of Pump Therapy Candidates

Assessment of the person with diabetes (PWD) is important in ensuring success with pump therapy. The diabetes care and education specialist must evaluate the physical and psychological readiness of each pump candidate to assume the responsibilities and challenges of pump therapy.

There are a number of clinical and lifestyle indicators and desired attributes that should be considered when performing a thorough assessment of whether a person is an appropriate candidate for insulin pump therapy. Some private insurance providers and all government-based insurers require additional documentation, such as a specific fasting blood glucose and C-peptide levels or antibody results.5

 

Clinical Indications for Insulin Pump Use

  • Persons with Type 1 diabetes or Type 2 diabetes requiring frequent multiple daily injections
  • Inadequate glycemic management despite optimized multiple daily injection therapy
  • High glucose variability
  • Elevated A1C
  • Recurrent, severe or unpredictable hypoglycemia
  • Nocturnal hypoglycemia
  • Hypoglycemia unawareness
  • Recurrent hyperglycemia
  • Dawn phenomenon
  • Preconception planning
  • Pregnancy
  • Extreme insulin sensitivity
  • Gastroparesis
  • Early neuropathy or nephropathy
  • Renal transplantation
  • Potentially persons with needle phobia
  • Lifestyle Indications
  • Erratic schedule
  • Varied work shifts
  • Frequent travel
  • Desire for flexibility
  • Inconvenience of multiple daily injections

 

Desired Attributes of a Pump Candidate (and/or parent(s) of pump candidate)

  • Motivation to succeed, as pump therapy requires readiness, preparedness and time investment before and during initiation
  • Realistic expectations of the capabilities of pump therapy
  • Demonstration of independent diabetes management and knowledge of the basics of diabetes education, including all topics listed in the National Standards for Diabetes Self-Management

Education and Support6

  • Ability to problem solve potential challenges with pump or infusion set malfunctions and how to maintain continuous insulin care in those circumstances
  • Ability to accept and deal with challenges that arise and check blood glucose levels consistently throughout the day or utilize CGM7, 11
  • Capacity to learn, practice and understand insulin pump therapy parameters such as insulin-to-carbohydrate ratios (ICR), correction or sensitivity factors (CF), and the application of the parameters to determine appropriate insulin dosing adjustments in response to hypoglycemia, hyperglycemia, stress, exercise and other personal parameters
  • Physical ability to view the pump screen and hear the alarms; dexterity to insert or charge the pump battery, fill and replace the insulin cartridge/reservoir in the pump; insert an infusion set; wear the pump; and perform the technical functions5
  • Emotional stability and adequate emotional support from family or significant others
  • Parents and caretakers must have a thorough understanding of pump therapy and willingness to spend the time needed to work with their child and health care professionals, when applicable
  • Patience and willingness to work with their health care provider during the time of pre-pump training and initiation; when appropriate basal rates, insulin-to-carbohydrate ratios and correction (sensitivity) factors are being determined
  • Adequate insurance benefits or personal resources to afford the cost of the pump and necessary supplies

Although these attributes are desired, they are not “requirements” for pump use. Diabetes care and education specialists are uniquely qualified to assist individuals in overcoming limitations or deficits to achieve optimal outcomes.

Regular assessments should be done to evaluate changes in a PWD’s clinical condition, motivation, abilities and life circumstances that may necessitate the need to reconsider appropriateness of pump therapy.

Considerations for Discontinuing an Insulin Pump

  • Lack of insurance or means to pay for an insulin pump and pump supplies
  • Change in physical or mental capacity to manage an insulin pump
  • Any suicidal ideation

 

References

Grouped by the claim each source supports. Primary and official sources — ADA, FDA, danatech, peer-reviewed — are tagged and listed first within each group. Compiled and verified July 2026.

2026 ADA Standards of Care & AID as preferred delivery
  1. 1. American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S150–S178. AID is the standard of care and preferred delivery method for people with type 1 diabetes who can safely use the device; rec. 7.27 supports open-source AID management advice.Primary
  2. 2. American Diabetes Association. ADA Releases "Standards of Care in Diabetes—2026." Press release, Dec 2025. Confirms new guidance removing prior treatment prerequisites before initiating CSII or AID.Primary
  3. 3. CGM: ADA 2026 Standards of Care. American Academy of Family Physicians. Documents Rec. 7.8a — no requirement for C-peptide, islet autoantibodies or insulin-treatment duration before CSII or AID.
What integration is — and why not every integrated pump is AID
  1. 4. Boughton CK, Hovorka R. Automated insulin delivery in adults. Review describing sensor-augmented pump therapy and low-glucose suspend / predictive low-glucose management as distinct from full AID.
  2. 5. Sensor-Augmented Insulin Pumps and Hypoglycemia Prevention in Type 1 Diabetes. Describes SAP with and without automated insulin suspension — the integration-without-full-AID category the page distinguishes.
  3. 6. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL). Diabetes Care. 2022;45(2):381. Contrasts closed-loop AID against SAP in "manual mode" with optional low-glucose suspend.
Meal input differs by system (including the iLet)
  1. 7. U.S. Food and Drug Administration. FDA Clears New Insulin Pump and Algorithm-Based Software (iLet). Confirms the iLet replaces conventional carb counting with a meal-announcement feature and initializes on body weight alone.Primary
  2. 8. danatech / ADCES. FDA Approves iLet Bionic Pancreas. danatech's own coverage of the meal-announcement mechanism.danatech
  3. 9. Beta Bionics. Meal Announcements Guide for iLet Bionic Pancreas. Manufacturer instruction: announce the meal when eating begins, not before; do not announce if more than 30 minutes have passed; do not use to correct highs.Manufacturer
Correction behavior, bolus workflow & insulin stacking
  1. 10. American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2026. (See ref. 1.) Supports individualized device selection and system-specific use rather than a single correction rule.Primary
  2. 11. Beta Bionics. Meal Announcements Guide for iLet Bionic Pancreas. (See ref. 9.) Instruction not to use meal announcements to correct a high, illustrating why correction workflow is system-specific.Manufacturer
CGM data gaps, questionable readings & confirming with a meter
  1. 12. diaTribe. Your Guide to the 2026 ADA Standards of Care. Summarizes the Standards' guidance to use a glucometer when CGM readings don't match symptoms, e.g. during warm-up periods.
  2. 13. American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2026. (See ref. 1.) Underlying recommendation for confirmatory glucose-meter use.Primary
Insulin-delivery failure: AID cannot confirm insulin is reaching the body
  1. 14. danatech / ADCES. Troubleshooting Unexplained Hyperglycemia. danatech's own step-by-step guidance: mechanical, behavioral and metabolic causes of unexplained highs; when to check ketones; when to seek emergency care for DKA.danatech
  2. 15. Howsmon DP, et al. Early Detection of Infusion Set Failure During Insulin Pump Therapy in Type 1 Diabetes. Confirms infusion-set failure can cause prolonged hyperglycemia or DKA, characterized by rising glucose despite increased insulin infusion.
  3. 16. Frequent Insulin Infusion Site Failures "a Huge Problem." Medscape, Mar 2026. Reports that a large share of AID users experience infusion-site failures; unexplained hyperglycemia can serve as a clinical proxy for undetected occlusion.

Primary = official ADA, FDA, danatech or peer-reviewed source. Manufacturer = manufacturer product or labeling page.

All URLs verified accessible July 2026. Device insulin clearances and indications should be confirmed against the current IFU. The page defers current-device specifics to Find & Compare, so no device-model citations are listed here.


The Danatech Digest

Join 25,000+ professionals who get our latest diabetes technology updates

DISCLAIMERS:

This site and its services do not constitute the practice of medical advice, diagnosis or treatment. Always talk to your diabetes care and education specialist or health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. To find a diabetes care and education specialist near you, visit the ADCES finder tool.

ADCES and danatech curate product specifics and periodically review them for accuracy and relevance. As a result, the information may or may not be the most recent. We recommend visiting the manufacturer's website for the latest details if you have any questions.


danatech is Made Possible by Grant Funding and Industry Sponsorship